Tumor specific delivery and therapy mediate by integrin β6-target immunoliposomes for β6-siRNA in colon carcinoma

// Liu Song 1 , Zhang Fan 2 , Niu Jun 3 , Liang Benjia 3 , Li Zequn 3 , Wang Xilong 1 , Jia Zhongming 1 , Han yong 1 , Wang Xiaohong 1 , Cheng Kai 1 , Yang Zhenlin 1 1 Department of Thyroid & Breast Surgery, Binzhou Medical College Affiliated Hospital, Binzhou 256600, Shandong, PR China 2 Department of Oncology, Binzhou Medical College Affiliated Hospital, Binzhou 256600, Shandong, PR China 3 Department of Hepatobiliary Surgery, Qilu Hospital of Shandong University, Jinan 250012, Shandong, PR China Correspondence to: Yang Zhenlin, email: yzhlin@126.com Keywords: colon carcinoma, integrinβ6, target therapy, immunoliposomes, siRNA Received: June 06, 2016      Accepted: October 21, 2016      Published: November 08, 2016 ABSTRACT Adjuvant chemotherapy does not achieve the desired therapeutic efficacy in colon cancer as a result of the deficient reaction. Gene therapy using small interfering RNAs (siRNAs) delivered by target delivering system represents a potent and specific strategy in tumor therapy. Integrinβ6 is exclusively expressed in malignant colonic epithelia, associated with the progression, metastasis, and chemotherapeutic resistance of colon cancer. Accordingly, designing an efficient and targeted delivery system for β6-siRNA could be a potential approach to improve therapeutic efficacy of colon cancer. Here, we designed the Integrinβ6 target immunoliposomes for highly efficient and selective delivery of β6-siRNA in colon cancer, which consequently resulted in greatly growth suppression, invasion and metastasis of colon cancer cells. Moreover, it was able to greatly inhibit the tumor growing in vivo.